June 25, 2020
COVID-19 and PIDs FAQs
IPOPI is monitoring the COVID-19 pandemic very closely and sharing evidence-based and expert validated information to the global primary immunodeficiency (PID) patients’ community and to our stakeholders. One of our most valuable tools is the COVID-19 and PIDs FAQs which are compiled with the help of our National Member Organisations (NMOs) and then answered in a series of Web Chats by our partner PID experts.
IPOPI has organised periodic Web Chats on Zoom with its members to help clear up their COVID-19 and PIDs doubts. Each NMO Web Chat addressed pertinent issues of the pandemic, such as, prevention, a potential vaccine, the nursing perspective, lessons learnt from China, supply of immunglobuling during and after the pandemic, how limited resouces countries address this healthcare crisis, among many others. IPOPI invited leading PID experts from accross the globe to discuss the questions raised by the NMOs and is keeping an updated COVID-19 and PIDs FAQs page.
The situation is evolving rapidly and affecting different regions of the world. Our priority is the safety of all PID patients and the safety of supply of their life-saving treatments both during and after the COVID-19 pandemic.
IPOPI has also taken part in similar regional calls and our Board Members remain very active in the regions of their responsability.